Privatsphäre-Einstellungen

On-going Stability Testing of Herbal Medicinal Products

Cornelia Höhne^1,7, Sven Oliver Kruse^2,7, Wolf Dammertz^3,7, Ulrike Kroll^4,7, Martin Tegtmeier^5,7, Barbara Steinhoff ^6,7

PhytoLab GmbH & Co. KG¹, Vestenbergsgreuth, Germany, Diapharm GmbH², Münster, Germany, H & S Tee-Gesellschaft mbH & Co. KG³, Kressbronn, Germany, Steigerwald Arzneimittelwerk GmbH⁴, Darmstadt, Germany, Schaper & Brümmer GmbH & Co. KG⁵, Salzgitter, Germany, Bundesverband der Arzneimittel-Hersteller e. V. (BAH)⁶, Bonn, Germany, on behalf of the BAH Working Group⁷

The principles used for stability testing of herbal medicinal products in the marketing authorisation/registration process apply for on-going stability studies as well. However, also for on-going stability testing the particular characteristics of herbal medicinal products must be taken into account. As some requirements like statistical evaluation and reaction on atypical trends and out-of-specification (OOS) results are difficult to implement for herbal medicinal products, practical approaches are proposed on how to handle critical and uncritical deviations. Critical deviations influence the overall quality, safety or efficacy of the product. They are regarded as confirmed OOS results in the sense of the EU GMP Guideline and should be reported to the competent authority. Minor OOS results may lead to further measures such as e. g. use of alternative markers or broadening of specification ranges, depending on the individual case. The intention of this article is to provide the Marketing Authorisation Holders (MAHs) and the responsible personnel, in particular the Qualified Persons (QPs), with a comprehensive overview on current practical experiences and to give support with regard to the interpretation of results and discussions with the competent authorities.